Canaccord Genuity Downgrades Pacira Pharmaceuticals (PCRX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Pacira Pharma (PCRX): Symphony Health Data Suggests Lower Q3 Revs - Jefferies
October 26, 2017 7:40 AM EDTJefferies analyst, David Steinberg, reiterated his Buy rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) and cut his price target to $57 from $59 after Symphony Health (SH) data indicates that Exparel achieved Sept sales of $21.5M (-6% M/M, -5% Y/Y).
The... More
Pacira Pharmaceuticals (PCRX) PT Lowered to $57 at Jefferies
October 26, 2017 6:45 AM EDTJefferies lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $57.00 (from $59.00) while maintaining a Buy rating.
Analyst Edward Chung remains positive on the name although Symphony Health data suggests lower Q3 revenues which drive the target cut.
... MoreJanney Montgomery Scott Downgrades Pacira Pharmaceuticals (PCRX) to Sell
October 26, 2017 6:43 AM EDTJanney Montgomery Scott downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Neutral to Sell.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $31.85 yesterday.
... More